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Abstract objectives To understand patients’ challenges in adhering to treatment for MDR-TB/HIV
co-infection within the context of their life circumstances and access to care and support.
methods Qualitative study using in-depth interviews with 12 HIV/MDR-TB co-infected patients
followed in a Me´decins Sans Frontie`res (MSF) clinic in Mumbai, India, five lay caregivers and ten
health professionals. The data were thematically analysed along three dimensions of patients’
experience of being and staying on treatment: physiological, psycho-social and structural.
results By the time patients and their families initiate treatment for co-infection, their financial and
emotional resources were often depleted. Side effects of the drugs were reported to be severe and
debilitating, and patients expressed the burden of care and stigma on the social and financial viability
of the household. Family caregivers were crucial to maintaining the mental and physical health of
patients, but reported high levels of fatigue and stress. Me´decins Sans Frontie`res providers recognised
that the barriers to patient adherence were fundamentally social, rather than medical, yet were
limited in their ability to support patients and their families.
conclusions The treatment of MDR-TB among HIV-infected patients on antiretroviral therapy is
hugely demanding for patients, caregivers and families. Current treatment regimens and case-holding
strategies are resource intensive and require high levels of support from family and lay caregivers to
encourage patient adherence and retention in care.
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Introduction
World Health Organization (WHO) (2010) estimates the
number of multidrug-resistant tuberculosis (MDR-TB)
cases in 2009 in India at 99 000 (79 000–120 000),
which represents approximately 25% of the global bur-
den of MDR-TB. The Indian Revised National TB Con-
trol Programme (RNTCP) has been scaling up diagnostic
and treatment services for MDR-TB (DOTS Plus) in a
phased manner across the country since 2009 (RNTCP
Annual Status Report 2012). However, because of limited
availability of accredited laboratories for culture and
drug susceptibility testing (DST), access to timely
diagnosis and treatment remains poor. Infection with
human immunodeficiency virus (HIV) further complicates
management of MDR-TB and poses an extremely
demanding treatment schedule for patients (World Health
Organization 2011). Both diseases remain highly stigma-
tised in the Indian context and patients struggle to access
affordable treatment and remain adherent (Kumarasamy
et al. 2005; Babu & Laxminarayan 2012).
Treatment adverse events, pill burden, rigidity of DOT,
psychosocial support and interaction with health person-
nel pose major challenges to adherence for concomitant
anti-TB and antiretroviral treatments (Munro et al. 2007;
Shargie & Lindtjørn 2007; Ingersoll & Cohen 2008; Sag-
bakken et al. 2008; Gebremariam et al. 2010; Toczek
et al. 2013). However, there are disappointingly few
studies that describe MDR-TB treatment experiences
from high HIV prevalence settings or among co-infected
patients (Mills et al. 2006; Munro et al. 2007; Johnston
et al. 2009; Orenstein et al. 2009; Gonzalez et al. 2011).
Understanding the challenges faced by HIV-infected
patients being treated for MDR-TB, their families and
their caregivers is essential for improving the quality of
care provided and the likelihood of retaining patients in
care. We report here from a qualitative study conducted
between April and October 2012 among HIV/MDR-TB
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co-infected patients registered with a clinic supported by
Me´decins Sans Frontie`res (MSF) in Mumbai, India. MSF
began treating MDR-TB among HIV-infected patients in
May 2007, and by April 2012, the cohort included 120
patients. Patients receive therapy through an ambulatory,
community-based programme that has been described
earlier (Isaakidis et al. 2011, 2012). Treatment regimens
are individualised, based on the first- and second-line drug
susceptibility testing (DST) results and on the patient’s
treatment history. Patients are treated for at least
20 months, based on WHO guidelines updated in 2011
and put on antiretroviral treatment (ART) for life follow-
ing the national ART protocol and WHO guidelines
(WHO 2010).Clinical and psychosocial needs of patients
are met by separate teams that function in consultation
with each other. All treatment, including investigations,
consultations, medications and counselling, as well as
hospitalisation if needed, is provided free of cost. Addi-
tional resources are used to trace a relatively small cohort
of defaulting patients, yet many patients are unable to stay
in care (Errol et al. 2012). The study draws on the perspec-
tives of patients, family and lay caregivers as well as formal
providers to explore the factors influencing treatment
adherence to ART and second-line TB treatment.
Methods
Twelve patients were purposively selected from the a
cohort of 33 patients who were receiving treatment for
MDR-TB and HIV from the MSF clinic in Mumbai,
India at the time of the study. The selection of patients
was made to adequately represent the influence of gender,
socio-economic characteristics and treatment phases on
the experience of being on treatment (Table 1).
Ten MSF healthcare providers working at the clinic and
in the community with co-infected patients were selected
to include all categories of staff; these included doctor
(n = 1), clinic nurses (n = 2), outreach nurses (n = 2),
nurse pharmacist (n = 1), social worker (n = 1), counsel-
lor (n = 1), peer educator (n = 1) and receptionist (n = 1).
Five lay (usually family) care providers (LCP), identified
by the researchers as providing substantial care and
support for the index patient, were purposively selected.
Data collection
Data collection took place between May and September
2012. Informed consent was obtained from all partici-
pants. In-depth interviews were conducted with patients
and care providers using flexible topic guides to allow for
open-ended answers and probing on emerging themes.
Patient interviews were conducted in Hindi or Marathi
and covered their experiences of help-seeking prior to
enrolment at the MSF clinic, care received from MSF
providers and their expectations regarding improved care
and support while on treatment. Interviews with lay pro-
viders elicited views on their roles and challenges in car-
ing for co-infected individuals on treatment. Interviews
Table 1 Profile of the sample patients
Patient ID† Sex Age Marital status Family support‡ Treatment buddy
Treatment status
(MDR-TB)
P1 Male 52 Married Lives with extended family Wife Completed
P2 Male 40 Married Lives with extended family Wife CP
P3 Male 50 Married Lives with extended family Wife (LCP2) CP
P4 Male 42 Married Lives with spouse; migrated to
Mumbai for treatment
Wife (LCP2) IP
P5 Female 37 Married Lives with extended family Husband (LCP3) IP
P6 Male 40 Married Lives with extended family Wife (LCP1) IP
P7 Male 39 Married Lives with extended family Wife (LCP4) IP
P8 Male 35 Married Lives with spouse; alienated
from wider family
Wife CP
P9 TG 25 Unmarried Lives alone Grandmother CP
P10 Female 35 Married Lives with spouse; alienated
from wider family
Husband (LCP5) IP
P11 Male 47 Married Lives with extended family Wife IP
P12 Female 34 Deserted Lives in institute for destitutes MSF staff member CP
P13 Male 38 Widowed Lives with extended family Brother IP
†The interview with P4 was not used in this article because the patient withdrew participation after partial interview.
‡In this population, the majority of households are extended or joint. It is unusual for a married couple to live separately from the
husband’s family.
CP, continuation phase; IP, intensive phase.
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with MSF providers focused on their roles in supporting
patients on treatment, and the challenges faced in patient
retention. The majority of interviews were recorded
using a digital recorder, transcribed and translated into
English. Notes were taken in cases where the respondents
did not wish to be recorded and expanded immediately
afterwards.
Data analysis
Data transcripts were reviewed on an ongoing basis, and
emerging themes that related both to our original ques-
tions as well as unanticipated areas were noted. At mid-
point through the study, the researchers began to develop
a set of codes relating to three broad dimensions of
patients’ experience of being on long-term treatment:
individual experience (physiological and psychological);
the impact on social relations including those within the
patients’ household; and patients’ engagement with the
health system and providers over the course of treatment
(structural). Once saturation was reached, the data were
indexed and manually analysed by two of the researchers.
Competing interpretations were resolved through ongoing
discussion.
Ethics
The study was approved by the Institutional Review
Board of The Maharashtra Association of Anthropologi-
cal Sciences – Centre for Health Research and Develop-
ment (MAAS-CHRD), Pune, India. The MSF Ethics
Review Board, Geneva, Switzerland reviewed the proto-
col and advised on the study. Patients were given infor-
mation about the purpose of the study and their role
within it, and informed consent was obtained from them
if they were available and willing to participate.
Results
Treatment experiences of patients co-infected with MDR-
TB and HIV were marked by numerous problems that
reflected a complex interplay of physiological, psychoso-
cial and structural challenges. We examined these dimen-
sions through close attention to the trajectory of patients
as they accessed, initiated and struggled to stay on
treatment with the support of family and organisational
care providers.
Accessing treatment: ‘the last chance’
Fragmented, non-integrated care and delays in initiation
of effective treatment for co-infection meant that patients’
resources were often depleted by the time they reached
MSF. Patients were often in critical condition, and their
families financially and emotionally exhausted from the
long help-seeking journey. For most patients, this journey
had included two rounds of treatment, for new and recur-
rent TB. Relating the case of a patient who died while on
treatment, an MSF peer educator highlighted the impact
of the high burden of care on her brother and mother,
who were ‘sapped of energy’ by the time they came to
MSF, ‘already very tired from years of taking care’.
While initiation on to treatment for MDR-TB and
ART at MSF represented an important turning point in
the trajectory of co-infected patients, it was also seen as
the last possible resort when all other options had failed:
‘There is no other treatment and no way out. This is the
end. There are no treatments after this, this is the last
chance’ (P6, male, 40 years).
Being on treatment
‘Worse than the illness itself’: side effects.
Once initiated on treatment, patients had to adjust to
daily doses of up to 21 tablets and intramuscular injec-
tions for 9–12 months, an extreme regimen associated
with severe and painful side effects:
‘I have to take them [medicines and injections] daily.
And I cry every day. Every day I cry for an hour …
the place where they give the injection becomes
stone hard. When I take the injection, I can’t lift my
legs, my legs hurt a lot and I am unable to walk. If
you give me pills, I will eat them. As many as you
want me to [eat]. I have no problems with that. The
injections are very painful. (P5, female, 37 years)’.
Side effects of MDR-TB drugs – nausea, vomiting, gid-
diness, lethargy, tinnitus, blurring of vision, depression,
suicidal tendencies – were described to be ‘as bad as or
worse than the illness itself’. The wife of P6 described
drastic changes in her husband’s temperament after he
started treatment:
‘He used to take the pills and that caused him to be
very uncomfortable and he would get short tem-
pered because of that. He would always say that he
is going to leave the house and go away. He was
not able to sleep night and day (…) He would lie
down in the loft upstairs after taking the pills and
would not want even a draft of air or a ray of light
in front of his eyes. He would stay there all day till
his dizziness passed away ( LCP1, female, 35 years)’.
P2, male, 40 years simply said: ‘I thought I was going
to die because of the medicines…it was that bad’.
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‘Stay separately or stay far away’: stigma and loss of sup-
port.
Apart from the physical challenges, many patients and
their families expressed the emotional strains of coming
to terms with what P1 described as ‘the worst of the
worst illnesses’. While both TB and HIV are considered
shameful diseases, patients considered HIV to be more
stigmatising than MDR-TB. Most patients had disclosed
their HIV status only to their spouses and parents, but
not to friends or the extended family. This limited
patients’ and their families’ chances of seeking social and
emotional support to cope:
‘I was dealing with it all by myself. I used to cry
quietly. My mother in law was also very sad when
she found out. (…) I only told her [my sister] and
no one else. She also said she would not tell anyone
as it was not something one can tell easily. She did
not even tell her husband. I did not even tell my
brother as his wife may just blurt it out in front of
other people. (LCP1, female, 35 years)’.
Several patients spoke about the embarrassment and
loss of self-respect in taking DOT at the doctor’s clinic:
‘I go to the doctor, there might be 4–5 patients over
there, and if I take medicines in front of them, then
they will ask ‘what is this medicine for?’ The doctor
will tell them that this man has HIV, then the way
other persons look at you changes, people try to
keep away from you. And sometimes I vomit, or
bring out sputum then they pinch their noses.
(P8, male, 35 years)’.
Some patients lost all support when diagnosed with co-
infection. In her 5th month of pregnancy, P12, 34 years,
was diagnosed as HIV positive. Her husband forced her
to terminate the pregnancy, but later abandoned her ‘as
he could not afford my treatment’. She sought shelter at
a church-run centre for PLHIV after her natal family
asked her to move out. P9, a male to female transgender,
25 years old, was asked to leave her transgender1 group
home when she was diagnosed with MDR-TB. Before she
became sick, she cooked for the group but once she was
diagnosed, the group members refused to eat what she
cooked and looked down upon her:
‘They say [you should] ‘be separate, eat separately,
keep your water separate, and stay separately or
stay far away’. I am very sad in my heart, my heart
aches because of this…. What can I do?’
‘I stopped going to work and stayed home’: the burden
of care.
Patients’ households were seriously socially and financially
affected by the burden of disease. Half of the patients
who were employed before they got sick (n = 5/10) had
not resumed work even after being on treatment for a
year or more and were consumed by worry and guilt for
not being able to contribute to the household. Often the
family members who cared for the patient needed to
organise their lives around the patient’s treatment sche-
dule. Spouses and family members attended to the
patient’s physical and emotional needs and took on their
social responsibilities as well. The husband of P10
(LCP5) had to take leave from work in order to accom-
pany her to the clinic. He commented: ‘Ever since my
wife has come into my life all I have been doing is going
to this hospital or that one. I don’t think there is a hospi-
tal left where we have not gone’. P6 lamented that his
wife had to do housework in other people’s houses due
to his inability to work, and his wife (LCP1, 35 years)
confirmed her husband’s complete dependency on her: ‘I
take care of him all day and I even stopped going to
work and stayed home for 3 months’.
Staying on treatment
‘They helped me find courage’: the role of organisational
and family support.
Me´decins Sans Frontie`res and family providers played a
key role in supporting patients to cope with the physical
and mental hardships associated with co-infection and its
treatment. Patients appreciated the empathy shown by
MSF care providers and the non-discriminatory environ-
ment of the clinic. P1, (male, 52 years old), for example,
suggested that the staff at MSF were very different from
‘other places [in which] even doctors are not nice to HIV/
TB patients’. P7 (male, 39 years old) felt that ‘the way
guidance is given here [at MSF] has itself made half my ill-
nesses go away’. P12 (female, 34 years old) detailed the
level of emotional and practical support that was provided:
‘They [MSF staff] stood by me. They gave me emo-
tional support, helped me find courage. R [nurse]
said if ever I did not feel well, or felt that I needed
to talk, I was to give her a missed call [on her
mobile phone] and then she would call back. (…) It
was like she was with me all the time, to help me
whenever I needed help. (…) They have cared for
me – more than my blood relatives.’
1
This patient was a member of the ‘hijra’ community where bio-
logical men identify themselves as women, adopt feminine
names, wear women’s clothing and may opt for ritual castration.
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Identifying and counselling a treatment ‘buddy’ to help
the patient complete treatment was one of the major
activities provided by the MSF patient support team. The
MSF social worker described their importance:
‘They [patients] are very disturbed psychologically…
they are very irritable and the family members or
buddies are fed up of all this. We try to explain to
them what kind of problems can come up if they do
not have the support of family members or buddies
and how to maintain that support (MSF social
worker, male, 35 years)’.
In the case of a patient who died, the clinic nurse sug-
gested it was the fact that ‘he had nobody’ which led him
to be ‘careless about treatment’. The nurse pharmacist,
on the other hand, highlighted the responsibility of rela-
tives to make sure patients took their medicines correctly
and on time. Some family members, she said ‘do this dili-
gently’ citing the example of a patient’s wife who took
out his daily medicines before she left for work. Lay care
providers’ accounts confirmed the extent of time and
energy expended in supporting patients on treatment:
‘Throughout the day I had to keep offering him
something to eat (…) If I was not there he would not
eat anything and would not bother with his diet (….)
He was not even able to walk. He would hold on to
me to walk. He could not even go to the bathroom.
We live in small rooms and the toilets are outside
but he used to sit for toilet in the house itself as he
was not able to walk till the toilets. I used to help
him with all of that (LCP1, female, 35 years)’.
This was not limited to spouses. P9, the transgender
staying in a pseudo-familial group, for example, talked
about her ‘grandmother’ (elderly leader of the group)
who would ‘keep a tab on whether I had my medicines
or not’ and tell her not to worry, as well as supporting
her with money for her transport.
‘When someone gets MDR [TB], why doesn’t anyone
come?’: the challenges of retention in care.
MSF care providers were often frustrated by the chal-
lenges of supporting patients and their families through
the arduous treatment especially when patients were lost
to follow up or their families failed to provide emotional
support. The MSF physician (female, 42 years), for
example, expressed some resentment that despite trying
so hard –‘we give 100% for the treatment of the
patients’, some patients were non-adherent. The non-
medical support staff, who helped patients keep their
appointments, described the effort needed to ensure
patients were regular:
‘There is one patient who has a hearing problem.
We always talk to her daughter. I have to make
reminder calls to her very often as her daughter for-
gets very often. It has happened many times. (…) So
now that I know she forgets, I make sure I remind
her even if I do not call anyone else. Once she did
not turn up for her 10 am appointment. I waited for
her till 10.30 and then when I called her she said
‘oh was there an appointment today? I did not
know’. (MSF receptionist, female, 33 years)’.
However, others recognised that adherence to medica-
tions was not just a medical issue. The MSF peer educa-
tor (male, 34 years) suggested that although MSF was
fully equipped to deal with the clinical aspects of adher-
ence, social aspects were more complex to address: ‘MSF,
they do 100–110% medically. Socially, we try our best,
but I feel maybe we [only] tackle about 80%. In our soci-
ety, if someone gets malaria, ten people will help him,
take him to hospital. When someone gets MDR [TB],
why doesn’t anyone come? Does anyone care for him?
(…). This is the reality’.
Discussion
To our knowledge, this is the first qualitative study of
patients with HIV and MDR-TB in India. While other
studies have looked at treatment adherence among people
on ART and among patients on second-line TB treat-
ment, this study is unique in triangulating the perspec-
tives of 12 HIV/MDR-TB co-infected patients and a
number of their lay and formal care providers in facing
the challenges of adhering to treatment. Our findings
reflect diversity in experiences and views. It is important
to note, however, that patients were drawn from a spe-
cific organisational cohort receiving free treatment and
care services that go far beyond the services offered in
public sector clinics; therefore, their experiences are not
representative of the wider affected community. Despite
the extent of support received from the MSF clinic,
patients found it extremely difficult to remain adherent;
the situation for patients who do not benefit from this
organisational support can be envisaged to be far worse.
This was indicated in part through our sampled patients’
accounts of their experiences of seeking treatment in the
private and public sector prior to reaching MSF, confirm-
ing the limited access that HIV/MDR-TB co-infected
patients in a large city like Mumbai continue to have.
Our sample of patients described side effects of the
drugs as being worse than the disease itself and detailed
the heavy social and financial burden of prolonged treat-
ment for two highly stigmatised diseases.
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Indeed, stigma emerged as an important barrier to
treatment seeking and adherence. Patients were embar-
rassed to follow DOT in facilities located in their neigh-
bourhoods. Stigma also led to non-disclosure of illness
resulting in further isolation of patients and lack of mo-
bilisation of additional support resources from family
and friends. Studies have shown that HIV-related stigma
may have a negative effect on TB treatment in co-infected
patients. Studies from Africa and South East Asia showed
that although both TB and HIV were stigmatised, more
stigma was attached to HIV, similar to our findings, and
that reasons for default in TB patients with HIV were
mostly to HIV-related stigma and discrimination (Ngam-
vithayapong et al. 2000; Daniel & Alausa 2006).
In the absence of patient- and provider-friendly treat-
ment regimens, interventions to ensure patients’ long-
term adherence to current treatment regimens are
resource-demanding – placing a high burden of care and
support on family and lay caregivers. Scale-up of diagno-
sis and treatment for MDR-TB and ART will, for the
near future, remain extremely challenging.
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